Capital One National Association’s Anika Therapeutics ANIK Stock Holding History

Capital One National Association’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-5,896	Closed	-$342K	–	516
2017 Q3	$342K	Buy	5,896 +134	+2%	+$7K	0.02%	417
2017 Q2	$284K	Sell	5,762 -24	-0.4%	-$1.1K	0.02%	439
2017 Q1	$251K	Buy	5,786 +483	+9%	+$23.1K	0.02%	461
2016 Q4	$260K	Sell	5,303 -142	-3%	-$6.57K	0.02%	442
2016 Q3	$261K	Buy	5,445 +282	+5%	+$13.9K	0.02%	443
2016 Q2	$277K	Buy	+5,163	New	+$243K	0.02%	435
2015 Q2	–	Sell	-7,532	Closed	-$310K	–	535
2015 Q1	$310K	Buy	7,532 +2,304	+44%	+$93.1K	0.03%	453
2014 Q4	$213K	Buy	+5,228	New	+$204K	0.02%	505
2014 Q3	–	Sell	-5,604	Closed	-$260K	–	526
2014 Q2	$260K	Buy	5,604 +5	+0.1%	+$222	0.02%	462
2014 Q1	$230K	Buy	+5,599	New	+$208K	0.02%	498

Other funds holding ANIK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AAM

AMI Asset Management Los Angeles, California $1.57B AUM 19.49% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return

TAM

THB Asset Management Norwalk, Connecticut $440M AUM 59.59% 1-Year Est. Return

Capital One National Association's ANIK Position: Q4 2017 in Review

Capital One National Association sold out of Anika Therapeutics (ANIK) in Q4 2017, closing a stake of 5,896 shares — an estimated $342K sold.

Capital One National Association first reported a position in ANIK in Q1 2014 and held it in 10 quarters. The position peaked at $342K in Q3 2017. 172 funds tracked by Wall St. Rank hold ANIK as of Q4 2017.

Capital One National Association reported no remaining Anika Therapeutics position as of Q4 2017 after selling out during the quarter.
Capital One National Association sold 5,896 Anika Therapeutics shares in Q4 2017, an estimated $342K.
Capital One National Association first reported a position in Anika Therapeutics in Q1 2014 and held it in 10 quarters.
Capital One National Association's Anika Therapeutics position peaked at $342K in Q3 2017.
172 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2017.

Based on Capital One National Association's 13F filing for Q4 2017, filed 7 Feb 2018.